Literature DB >> 15291573

Antibody-catalyzed oxy-cope rearrangement: mechanism and origins of catalysis and stereoselectivity from DFT quantum mechanics and flexible docking.

Kersey A Black1, Andrew G Leach, M Yashar S Kalani, K N Houk.   

Abstract

Density functional theory using B3LYP and flexible ligand docking methods were used to investigate the complete potential surface for the uncatalyzed and the AZ28 antibody-catalyzed oxy-Cope reaction of 2,5-diaryl-1,5-hexadien-3-ol derivatives. The reaction mechanism is stepwise, involving a cyclohexane diyl intermediate. Theoretical deuterium isotope effects match well with those from experiment. Gas-phase transition structures show mixed preferences for the axial vs equatorial hydroxyl group, while solvation favors the axial isomer. Specific phenyl group conformations are shown to be critical to transition-state stabilization (by up to 15 kcal/mol), and the effective conformation is not that found in the hapten used to generate the germline and affinity-matured AZ28 catalytic antibodies. Docking studies support greater transition-state binding than reactant binding. Docking studies also predict the S stereoselectivity of mature AZ28 and suggest that binding modes quite different from those of the hapten might play a role in catalysis, with specific focus on ligand hydrogen bonding to Asp(H101).

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15291573     DOI: 10.1021/ja048604g

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  2 in total

1.  Enantioselective Catalysis of an Anionic Oxy-Cope Rearrangement Enabled by Synergistic Ion Binding.

Authors:  C Rose Kennedy; Bo Young Choi; Mary-Grace R Reeves; Eric N Jacobsen
Journal:  Isr J Chem       Date:  2020-03-06       Impact factor: 3.333

2.  Are boat transition states likely to occur in Cope rearrangements? A DFT study of the biogenesis of germacranes.

Authors:  José Enrique Barquera-Lozada; Gabriel Cuevas
Journal:  Beilstein J Org Chem       Date:  2017-09-19       Impact factor: 2.883

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.